benefits of glp-1 tirzepatide Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role | Cardiovascular Diabetology GLP-1 medications are marketed to

These same children born into a family with no history of T1D still have a 1 in 20 chance of developing T1D

Research from the STEP 1 trial published in the New England Journal of Medicine showed that only 4.3 percent of participants discontinued treatment due to GI adverse events when following the proper titration schedule

R., Pathmasiri K

Orlistat, a lipase inhibitor that reduces fat absorption, represents an alternative pharmacological option for adults with a BMI 30 kg/m or 28 kg/m with risk factors

It is associated with increased BDNF activity, improved cerebral blood flow, and enhanced cognitive resilience

: , ,